Today there was no big deal, no government decision, no surprise. The market barely moved: COMPASS Pathways, one of the main psychedelic companies, slipped less than two percent, and the others sat nearly flat. The freshest thing in the air is the growing conversation around a small pilot study — a first, early test — that gave psilocybin, the active ingredient in magic mushrooms, to a handful of military veterans suffering from PTSD, the deep trauma many carry home from war. The early signs looked encouraging. But here is the honest catch: the study had no comparison group. That means there were no similar patients who took a fake pill instead, so we can't be fully sure the improvement came from the drug and not from hope, attention, or time. The people who ran the study are expected to say this plainly themselves, and outside experts are already lining up to point it out.
Beneath the headlines, a familiar rhythm is playing out. A hopeful early result arrives. Politicians grab it and mention it in speeches and proposed laws, because it moves hearts. Then scientists step in and gently insist on stronger proof before anyone changes the rules. That is not a fight between good and bad — it is how trust gets built. The government agencies that approve drugs and control restricted substances don't move on excitement or a single small study. They move on solid, repeatable evidence. So the most likely path from here is not a sudden breakthrough but a bigger, more careful follow-up study — the kind that turns a hopeful hunch into something a doctor can stand behind. That slower road is actually the good news. It means that if psilocybin does help veterans, the proof will be strong enough to last, not something that crumbles under the first hard question.
For the veterans inside this story, the feeling is likely a mix of hope and caution held together. Many have tried everything — years of pills, therapy, sleepless nights — and heard promises before. To see their pain finally taken seriously in the halls of power means something real. But they also know the danger of being handed hope too fast, only to watch it get walked back. The highest outcome for them is not a rushed headline. It is a treatment that has been tested properly, so that when it reaches them, it holds. That is worth the wait, even when the waiting is hard. Honesty about what we don't yet know is not a betrayal of that hope — it is the thing that protects it.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
The current is already moving. You are already in it.
75%
The US drug agency won't review psilocybin's legal status soon
The DEA (the US Drug Enforcement Administration, which controls what drugs are legal) is very unlikely to start a formal review of psilocybin's status as a banned substance in the next three months. This matters because rescheduling — moving psilocybin off the most restricted drug list — is the main legal barrier stopping doctors from prescribing it widely. Without a DEA review, that barrier stays in place.
→ The federal government is almost certainly not starting any official process to change psilocybin's legal status in the next three months.
Resolves: 2026-10-24 · USA
REGULATORY
the precise call ▾
No DEA rescheduling notice or scheduling review for psilocybin is initiated within 12 weeks.. No congressional mandate is moving; DEA acts on statute and evidence, not pilot studies or advocacy.
72%
Veteran psilocybin study gets political buzz but no FDA response
A small government-funded pilot study giving psilocybin to veterans with PTSD (post-traumatic stress disorder) is likely to get mentioned in at least two speeches or proposed amendments in Congress. But the FDA (the US Food and Drug Administration, which decides what medical treatments are approved) almost certainly won't issue any formal response or new guidance because of it. A single small pilot study — especially one without a control group — doesn't carry enough scientific weight to make regulators act.
→ The veteran psilocybin study will generate political headlines but zero formal action from the FDA through at least mid-October 2026.
Resolves: 2026-10-10 · USA
REGULATORY
the precise call ▾
The veteran psilocybin PTSD pilot will be cited in ≥2 congressional statements/amendments but generate no FDA guidance response within 10 weeks.. Advocacy value outstrips evidentiary weight; FDA does not respond to open-label pilots with formal action.
70%
No FDA expert panel meeting for Compass's depression drug before mid-October
Before the FDA approves a new drug, it often convenes an advisory committee — a panel of outside experts who publicly review the evidence and vote on whether the drug seems safe and effective. Compass Pathways hasn't yet submitted a full application for COMP360 as a treatment for hard-to-treat depression, and the FDA has many competing priorities. So no scheduling notice for such a panel meeting is expected before October 15, 2026.
→ The FDA won't announce any expert review panel for Compass Pathways' psilocybin drug before October 15, 2026.
Resolves: 2026-10-15 · USA
REGULATORY
the precise call ▾
COMPASS Pathways' COMP360 Phase 3 (TRD) will not receive an FDA advisory committee scheduling notice before 2026-10-15.. No filing signal today; FDA bandwidth consumed elsewhere. Rigorous review timelines don't compress on political enthusiasm alone.
72%
Compass Pathways stock likely stays below $12.50 through September
CMPS is the stock ticker for Compass Pathways, a company developing a synthetic psilocybin drug called COMP360. With no major trial results or big business deals expected before the end of September 2026, the stock is likely to keep drifting at or below $12.50 per share. Without a concrete reason for large investors to buy in, there's no force pushing the price up.
→ Compass Pathways stock will likely stay below $12.50 all the way through September 2026 unless something big and unexpected happens.
Resolves: 2026-09-30 · Global
MARKETS
the precise call ▾
CMPS closes below $12.50 every trading day through 2026-09-30 absent a Phase 3 readout or partnership.. No near-term catalyst on the calendar; the pilot doesn't move institutional models. Downward drift continues.
68%
Veteran psilocybin study will face public scientific criticism within weeks
Within about six weeks, scientists and journalists are likely to publicly point out a major flaw in the veteran PTSD psilocybin pilot: it didn't use a control group (a comparison group of people who got a placebo or different treatment). Without that, you can't know whether the improvement veterans showed was caused by the psilocybin or by other factors like hope, attention, and care. This kind of critique is standard in science, but it matters here because it will likely limit how seriously the FDA and DEA treat the study.
→ Within roughly six weeks, credible scientists will publicly call out the veteran psilocybin study for lacking a control group, limiting its impact on regulators and markets.
Resolves: 2026-10-30 · USA
CLINICAL
the precise call ▾
The veteran psilocybin PTSD pilot drives political citation but is treated as non-pivotal by FDA/DEA/markets; a methodological corrective (control-arm critique) follows within ~6 weeks.. Consensus of 4 agents: fda_reviewer, journalist, neuroscientist. 2 dissenting.